Circe Biomedical Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Employees
-
25
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$26M
Circe Biomedical General Information
Description
Developer of bioartificial organs from isolated mammalian cells and membranes for patients suffering from acute, end-stage liver failure. The company's product HepatAssist® Liver Support System integrates viable liver cells with biocompatible membranes into an extracorporeal, bioartificial liver assist system.
Contact Information
Website
www.circebio.comCorporate Office
- 99 Hayden Avenue
- Lexington, MA 02421
- United States
Corporate Office
- 99 Hayden Avenue
- Lexington, MA 02421
- United States
Circe Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 11-Mar-2002 | $26M | Completed | Product Development | ||
| 2. Later Stage VC (Series C) | 18-Dec-2000 | Completed | Product Development | |||
| 1. Early Stage VC | 07-Apr-1999 | $16.4M | $16.4M | Completed | Product Development |
Circe Biomedical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 799,920 | $0.010000 | $0.5 | $0.5 | 1x | $0.5 | 1.6% |
Circe Biomedical Patents
Circe Biomedical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2382109-A1 | Astrocyte apparatus for bioprocessing a circulating fluid | Inactive | 23-Aug-1999 | ||
| EP-1220889-A1 | Astrocyte apparatus for bioprocessing a circulating fluid | Inactive | 23-Aug-1999 | ||
| WO-2001014516-A1 | Astrocyte apparatus for bioprocessing a circulating fluid | Inactive | 23-Aug-1999 | ||
| US-6136593-A | Device for the removal of toxins from blood | Inactive | 23-Aug-1999 | ||
| US-6300054-B1 | Removing toxins from biological fluids by treating the fluid with astocytes in vitro; therapy for liver failure | Inactive | 23-Aug-1999 | A61M1/3472 |
Circe Biomedical Signals
Circe Biomedical Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advanced Technology Ventures | Venture Capital | Minority | ||
| Asahi Chemical | Corporation | Minority | ||
| BancBoston Ventures | Venture Capital | Minority | ||
| Bessemer Venture Partners | Venture Capital | Minority | ||
| Burrill & Co | Merchant Banking Firm | Minority |
Circe Biomedical FAQs
-
When was Circe Biomedical founded?
Circe Biomedical was founded in 1996.
-
Where is Circe Biomedical headquartered?
Circe Biomedical is headquartered in Lexington, MA.
-
What is the size of Circe Biomedical?
Circe Biomedical has 25 total employees.
-
What industry is Circe Biomedical in?
Circe Biomedical’s primary industry is Therapeutic Devices.
-
Is Circe Biomedical a private or public company?
Circe Biomedical is a Private company.
-
What is the current valuation of Circe Biomedical?
The current valuation of Circe Biomedical is .
-
What is Circe Biomedical’s current revenue?
The current revenue for Circe Biomedical is .
-
How much funding has Circe Biomedical raised over time?
Circe Biomedical has raised $44.4M.
-
Who are Circe Biomedical’s investors?
Advanced Technology Ventures, Asahi Chemical, BancBoston Ventures, Bessemer Venture Partners, and Burrill & Co are 5 of 10 investors who have invested in Circe Biomedical.
-
When was Circe Biomedical acquired?
Circe Biomedical was acquired on 11-Mar-2002.
-
Who acquired Circe Biomedical?
Circe Biomedical was acquired by Bausch Health Companies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process